EPO Berlin is a preclinical contract research organization (CRO) that specializes in oncology and immuno-oncology services for the development of anti-cancer drugs. With 25 years of experience, EPO offers a comprehensive range of customized services to researchers and pharmaceutical companies worldwide. Their portfolio includes over 600 well-characterized patient- and cell line-derived xenograft tumor models, as well as syngeneic tumor models, covering a wide range of cancer entities.

EPO also has expertise in the establishment of humanized models and has been conducting studies in this field for over a decade. EPO's highly qualified team, including more than 20 PhD holders, ensures quick response and turnaround times, flexible study design, regular updates, and transparent communication. Their scientists regularly contribute to scientific papers in esteemed international journals and present at national and international cancer conferences.

Located on the Research Campus Berlin-Buch, EPO operates from a state-of-the-art laboratory space spanning over 1300 m² (12,000 sqf). With a strong commitment to scientific excellence, EPO is driven by passion and dedicated to serving the scientific community